Lumito

Lumito is a pioneering diagnostics company commercializing a novel tissue imaging platform centered on upconverting nanoparticles (UCNPs), which offer ultra-sensitive detection without autofluorescence. Its core product, the SCIZYS system, enables high-accuracy quantification of biomarkers, targeting critical needs in precision oncology (e.g., HER2 low/ultralow expression) and translational research. The company is transitioning from development to early commercial engagements, leveraging a scalable 'Scan-as-a-Service' model and strategic partnerships to penetrate the growing digital pathology market.

Upconverting Nanoparticle (UCNP) technology for ultra-sensitive, quantitative, and autofluorescence-free digital tissue imaging and biomarker detection.

Lumito competes in the digital pathology and advanced multiplexed tissue imaging market. Key competitors include companies like Akoya Biosciences (PhenoImager, CODEX), Lunaphore (COMET), and Visiopharm, which offer alternative multiplexing and quantification platforms. Lumito's differentiation lies in the unique physics of UCNPs, offering superior sensitivity and no autofluorescence.